Compound Summary
Compound Information
Semaxanib
Compound Name: | Semaxanib |
Compound CID: | 5329098 |
Synonyms: | Semaxanib SU5416 Semaxinib SU 5416 204005-46-9 More... |
Iupac Name: | (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one |
InChI: | InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8- |
InChIKey: | WUWDLXZGHZSWQZ-WQLSENKSSA-N |
Canonical Smiles: | CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C |
Isomeric Smiles: | CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C |
Molecular Weight: | 238.28 |
Molecular Formula: | C15H14N2O |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Semaxanib
Molecular Weight: | 238.28 |
Molecular Formula: | C15H14N2O |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 1 |
Rotatable Bond Count: | 1 |
Heavy Atom Count: | 18 |
Complexity: | 377 |
Synonyms
Semaxanib
| Semaxanib | Semaxanib |
|---|---|
Semaxanib |
SU5416 |
Semaxinib |
SU 5416 |
204005-46-9 |
194413-58-6 |
Semoxind |
SU-5416 |
Semaxanib (SU5416) |
TSU 16 |
Z-Semaxanib |
UNII-71IA9S35AJ |
VEGF Receptor 2 Kinase Inhibitor III |
(Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one |
NSC-696819 |
(3Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)methylidene-1H-indol-2-one |
(Z)-SU 5416 |
71IA9S35AJ |
CHEMBL276711 |
(3Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)methylidene-1,3-dihydro-2H-indol-2-one |
3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole |
3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone |
Semaxnib |
Sugen 5416 |
3-(3,5-dimethyl-1H-pyrrol-2-yl)methylidene-1,3-dihydro-2H-indol-2-one |
(3Z)-3-(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE-2,3-DIHYDRO-1H-INDOL-2-ONE |
3-(2,4-Dimethylpyrrol-5-yl)methylidene-indolin-2-one |
Semaxanib(SU5416) |
SMR000568416 |
TSU-16 |
SR-01000076044 |
Semaxanib (USAN/INN) |
Semaxanib USAN:INN |
methylene-2H-indol-2-one |
VEGFR2 Kinase Inhibitor III |
(Z)-Semaxinib |
NCGC00094381-03 |
3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one |
NSC 696819 |
2x2m |
Semaxanib; SU5416 |
1,3-Dihydro-3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene-2H-indol-2-one |
H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro- |
S 8442 |
SCHEMBL8190 |
Lopac0_001110 |
SCHEMBL19571 |
1,3-Dihydro-3-(3,5-dimethyl-1H-pyrrol-2-yl) |
MLS001074896 |
MLS001332519 |
MLS001332520 |
BDBM4810 |
GTPL5056 |
QCR-86 |
3-(2,4-dimethylpyrrol-5-yl)methylidenylindolin-2-one |
InSolution™ VEGF Receptor 2 Kinase Inhibitor III |
CHEBI:91083 |
cid_5329098 |
AOB6828 |
BDBM497339 |
HMS2234L12 |
HMS3229O13 |
HMS3263M22 |
HMS3268J13 |
HMS3413H10 |
HMS3648O12 |
HMS3677H10 |
AMY10847 |
BCP06068 |
EX-A2158 |
Tox21 111271 |
Tox21_501110 |
2033AH |
2712AH |
HSCI1_000303 |
MFCD01940922 |
NSC696819 |
s2845 |
SU5146 |
ZINC12410091 |
3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene-1,3-dihydro-2h-indol-2-one |
AKOS015994557 |
CCG-205186 |
CS-1225 |
DB06436 |
ES-0010 |
LP01110 |
SDCCGSBI-0051079.P003 |
US11001595, Compound SU5416 |
NCGC00094381-01 |
NCGC00094381-02 |
NCGC00094381-04 |
NCGC00094381-05 |
NCGC00094381-19 |
NCGC00261795-01 |
HY-10374 |
QC-11357 |
SU005416 |
AB0094985 |
EU-0101110 |
SW219791-1 |
D05819 |
N11132 |
A857052 |
A899499 |
2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene- |
J-013281 |
Q7449140 |
SR-01000076044-2 |
SR-01000076044-8 |
BRD-K63504947-001-05-5 |
3-(2,4-Dimethylpyrrol-5-yl)methylidenyl-2-indolinon |
3-(2,4-dimethylpyrrol-5-yl)methylidenyl-2-indolinone |
3-(2,4-dimethylpyrrol-5-yl)methylidenyl-indolin-2-one |
Semaxanib, Semoxind, TSU-16, NSC-696819, SU-5416 |
3-(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl-1H-indol-2-ol |
3-(3,5-Dimethyl-1H-pyrrol-2-yl)methylene-1,3-dihydro- 2H-indol-2-one |
(3Z)-3-(3,5-Dimethyl-1H-pyrrol-2-yl)methylene-1,3-dihydro-2H-indol-2-one |
2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)- |
2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)- |
2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)- |
2H-Indol-2-one,3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene-1,3-dihydro-, (3Z)- |
3-1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene-2-oxo-2,3-dihydro-indole |
Experimental Data
Semaxanib
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | -13 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
Semaxanib
Statistics Data
Semaxanib
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -13 | 1 | 1 |
Statistics Data Visualization
Semaxanib
